EVERO Drug-coated Balloon (DCB) Randomized Trial (NCT07144150)
Advance Evero™ 18 Everolimus-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter Versus Paclitaxel-coated Ballons in Patients With Femoropopliteal Disease (EVERO Trial)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).
Who can join: Review the eligibility criteria below.
Location: Yale New Haven Hospital — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Yale New Haven Hospital — New Haven, Connecticut
- The Cardiac and Vascular Institute — Gainesville, Florida
- First Coast Cardiovascular Institute — Jacksonville, Florida
- Baptist Cardiac and Vascular Institute — Miami, Florida
- Midwest Cardiovascular Research Foundation — Davenport, Iowa
- North Mississippi Medical Center — Tupelo, Mississippi
- Prisma Health Memorial — Greenville, South Carolina
- Houston Methodist Hospital — Houston, Texas
📞 Contact the Study Coordinator
Phone: (765) 463-7537
Email: noah.shields@cookmedical.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Peripheral Vascular Disease
- Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O. — Vancouver, British Columbia
Explore by condition: All Peripheral Vascular Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.